‘If I am playing football, I forget that I have this virus’: the challenges and coping strategies of adolescents with perinatally acquired HIV in KwaZulu-Natal, South Africa

Abstract

Background Adolescents who have acquired HIV perinatally (ALHIV) face unique challenges in taking lifelong antiretroviral therapy (ART), but little is known about what factors affect their adherence over the course of their lifelong treatment journey. Methods We conducted a qualitative study with ALHIV who had periods of poor adherence to ART in KwaZulu-Natal, South Africa using Participant-generated Visual Methodologies (PVM). Participants used photography to represent their perspectives and experiences. Results 14 individuals participated in the research process. We developed a framework and identified four social domains which combined with the adolescent’s own experiences and sense of self to either support or undermine adherence. Periods of non-adherence were reported by all participants. Participants described the importance of supportive relationships and households as well as the benefits of ART as supporting adherence. The fear of inadvertent disclosure of their HIV status and the side-effects of ART were barriers to adherence. Possible interventions to support adolescents in their treatment journey are identified. Conclusions Current models of adherence support fail to address the challenges to lifelong therapy ALHIV face. Ongoing education and honest communication with health care providers, interventions that build resilience together with peer support, have the potential to improve adherence in ALHIV.

Resistencia a los inhibidores de la integrasa en niños con el virus de la inmunodeficiencia humana por transmisión vertical: primeros casos en Uruguay

“…La frecuencia y modalidad se ajustará a cada paciente, a sus redes, a creencias, así como a las características del medicamento que recibe (presentaciones farmacéuticas, eficacia y barrera genética). 12,13…”

Resistance to integrase inhibitors in children with vertically-transmitted human immunodeficiency virus: First cases in Uruguay

“…Monitoring frequency and modality will be adjusted to each patient, their networks, their beliefs, and the characteristics of the drugs they receive (pharmaceutical forms, effectiveness, and genetic barrier). 12,13…”